Immunovant, Inc.
IMVT- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001764013
In the last 90 days, Immunovant, Inc. insiders filed 0 open-market purchases and 10 sales; 226 institutions reported holding it in 13F filings for Q2 2026, worth $4.25B in total; Greenlight Capital is the only superinvestor holding it.
Q1 2026 vs. Q4 2025
How the institutions holding Immunovant, Inc. changed between Q4 2025 and Q1 2026.
All holders in Q1 2026All holders in Q4 2025
| Measure | Q4 2025 | Of which not filed for Q1 2026 | Q1 2026 | Change |
|---|---|---|---|---|
| Holders | 197 | 2 | 216 | +21 |
| Shares | 108.6M | 7.78M | 110.6M | +9.77M (+9.7%) |
| Value | $2.76B | $197.8M | $2.75B | +$183.5M (+7.2%) |
2 institutions that held it in Q4 2025 haven't filed for Q1 2026 yet. Not filing isn't selling, so the changes leave them out.
New holders (46)
Institutions that held Immunovant, Inc. at the end of Q1 2026 but not at the end of Q4 2025.
Sold out (25)
Institutions that held Immunovant, Inc. at the end of Q4 2025 and filed for Q1 2026 without it.
| Institution | Shares, Q4 2025 | Value, Q4 2025 |
|---|---|---|
| Point72 Asset Management, L.P. | 2,000,000 | $50.8M |
| Millennium Management LLC | 172,496 | $4.38M |
| Exome Asset Management LLC | 158,622 | $4.03M |
| Verition Fund Management LLC | 80,794 | $2.05M |
| Prelude Capital Management, LLC | 41,683 | $1.06M |
| Ishara Investments LP | 30,000 | $762.6K |
| Tudor Investment Corp Et Al | 25,600 | $650.8K |
| Y-Intercept (Hong Kong) Ltd | 21,002 | $533.9K |
| DnB Asset Management AS | 18,109 | $460.3K |
| Altfest L J & Co Inc | 17,867 | $454.2K |
| Caption Management, LLC | 16,000 | $406.7K |
| VARCOV Co. | 15,887 | $403.8K |
| Headlands Technologies LLC | 14,212 | $361.3K |
| Arrowpoint Investment Partners (Singapore) Pte. Ltd. | 13,714 | $348.6K |
| Quest Partners LLC | 9,326 | $237.1K |
| Quarry LP | 3,000 | $76.3K |
| Amalgamated Bank | 2,203 | $56.0K |
| Daiwa Securities Group Inc. | 501 | $13.0K |
| Meeder Asset Management Inc | 192 | $4.88K |
| SRS Capital Advisors, Inc. | 102 | $2.59K |
| CoreCap Advisors, LLC | 55 | $1.40K |
| Basecamp Wealth Advisors LLC | 31 | $788 |
| Torren Management, LLC | 21 | $534 |
| SageView Advisory Group, LLC | 15 | $382 |
| Dunhill Financial, LLC | 1 | $24 |
Not filed for Q1 2026 yet (2)
Institutions that held Immunovant, Inc. at the end of Q4 2025 and haven't filed a 13F for Q1 2026. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q4 2025 | Value, Q4 2025 |
|---|---|---|
| Vanguard Group Inc | 7,779,314 | $197.8M |
| Comerica Bank | 319 | $8.11K |